PTGES and inborn mitochondrial metabolism disorder: Inhibition of the microsomal prostaglandin E synthase-1 (mPGES-1) by sonlicromanol (Khondrion; a drug currently in phase 2b studies for mitochondrial disease), may also be beneficial in COVID-19 patients (Fig 6A).